Business Context and Reporting Period
Company: Pfizer Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended July 1, 2007
Business Overview: Pfizer is a global, research-based pharmaceutical company. The reporting period reflects the impact of the December 2006 sale of its Consumer Healthcare business (now reported as discontinued operations), the loss of U.S. patent exclusivity for key products (Zoloft, Norvasc), and the ongoing "Adapting to Scale" (AtS) productivity initiative.
Key Financial Metrics
| Metric (in millions) | Q2 2007 | Q2 2006 | 6 Months 2007 | 6 Months 2006 |
|---|---|---|---|---|
| Revenues | $11,084 | $11,741 | $23,558 | $23,488 |
| Net Income | $1,267 | $2,415 | $4,659 | $6,526 |
| Diluted EPS | $0.18 | $0.33 | $0.66 | $0.89 |
| Operating Cash Flow (6mo) | $4,908 (vs. $9,104 in 2006) | |||
| Total Debt | $8,209 (Short-term: $2,432; Long-term: $5,777) | |||
| Cash & Short-term Investments | $22,253 (Cash: $2,138; ST Inv: $20,115) | |||
| Working Capital | $26,486 |
Material Changes vs. Prior Period
- Revenue Decline: Q2 2007 revenues decreased 6% year-over-year. The decline was driven by the loss of U.S. exclusivity for Zoloft (-82% revenue impact) and Norvasc (-45% revenue impact), and competitive pressures on Lipitor (-13% revenue impact). These were partially offset by growth in new products like Chantix/Champix, Lyrica, and Sutent.
- Profitability Compression: Net income dropped 48% in Q2 and 29% for the six-month period. This was primarily due to higher restructuring costs ($1.05 billion in Q2 vs. $268 million in Q2 2006) associated with the AtS initiative, increased R&D expenses (including a $250 million upfront payment to Bristol-Myers Squibb), and the absence of one-time tax benefits recorded in 2006.
- Discontinued Operations: The former Consumer Healthcare business, sold in December 2006, resulted in a net loss of $78 million in Q2 2007 compared to income of $125 million in Q2 2006.
- Cost Structure: Cost of sales increased 18% in Q2, and R&D expenses increased 24%, largely due to the timing of collaboration payments and implementation costs for the productivity initiative.
Guidance, Outlook, and Risks
Management Guidance (Full Year 2007)
- Revenues: Expected to be between $47 billion and $48 billion.
- Reported Diluted EPS: Expected to be between $1.30 and $1.41.
- Adjusted Diluted EPS: Expected to be between $2.08 and $2.15.
- Cash Flow: Operating cash flow expected to be $12 billion to $13 billion.
- Share Repurchases: Company expects to purchase up to $10 billion of stock in 2007.
Key Risks and Contingencies
- Patent Litigation: Adverse court decisions regarding Norvasc (U.S. exclusivity lost early) and ongoing challenges to Lipitor patents in Canada and the U.S. (Teva, Ranbaxy).
- Product Liability: Ongoing litigation regarding the 1996 Trovan clinical study in Nigeria (civil actions filed by Nigerian authorities) and Neurontin marketing practices.
- Regulatory: FDA label changes for antidepressants (Zoloft) and potential impacts on product sales.
- Accounting Changes: Adoption of FIN 48 (Accounting for Uncertainty in Income Taxes) resulted in a reclassification of approximately $4.0 billion of tax liabilities from current to non-current.
Investor Verification Checklist
- Patent Status: Verify the current status of the Lipitor patent litigation in Canada and the U.S., as this impacts the company's largest revenue generator.
- Restructuring Costs: Monitor the execution and cost savings realization of the "Adapting to Scale" initiative, which significantly impacted current earnings.
- Product Mix: Assess the growth trajectory of new products (Lyrica, Chantix, Sutent) relative to the decline of legacy products (Zoloft, Norvasc, Lipitor).
- Tax Liabilities: Review the impact of the FIN 48 adoption on future tax provisions and cash flows, given the large reclassification of uncertain tax positions.
- Legal Exposure: Track developments in the Trovan and Neurontin litigation for potential settlement costs or judgments.